Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice

Download this slideset based on the content from a live-stream CCO series from Paul G. Richardson on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after first-line therapy.

Paul G. Richardson, MD
Program Director Released: June 23, 2021

Download this slideset based on the content from a live-stream CCO series from Peter M. Voorhees, MD on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after multiple lines of therapy.

Peter M. Voorhees, MD Released: June 24, 2021

Download this slideset based on the content from a live-stream CCO series from Nina Shah, MD on novel therapies under investigation for patients with relapsed/refractory multiple myeloma, including CAR T-cell therapies, bispecific antibodies, antibody drug conjugates, and CELMoDs.

Nina Shah, MD Released: June 24, 2021

Gain key clinical insights fast, with this short summary slideset from CCO on key considerations for optimal treatment selection for patients with relapsed/refractory myeloma.

Paul G. Richardson, MD
Program Director Nina Shah, MD Peter M. Voorhees, MD Released: June 25, 2021